MENDUS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.47 SEK | -3.09% |
|
+2.29% | -10.13% |
| 16/04 | Mendus AB Announces Board Changes | CI |
| 27/03 | Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MENDUS AB | Other Biotechnology & Medical Research | -3.09% | +2.29% | -10.13% | -63.85% | -94.03% | 45.04M |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- IMMU Stock
- Charts Mendus AB
- Comparison Chart